Valence Life Sciences
Portfolio 8
| Date | Name | Website | Total Raised | Location |
| - | Atea Pharm... | ateapharma.com | $215M | United Sta... |
| - | VIVUS Inc. | vivus.com | $33.6M | United Sta... |
| - | ArQule | arqule.com | - | United Sta... |
| - | Leap Thera... | leaptx.com | $90M | United Sta... |
| - | gentium | gentium.it | - | - |
| - | Jazz Pharm... | jazzpharma.com | $179M | Ireland, D... |
| - | CalciMedic... | calcimedica.com | $36M | United Sta... |
| - | Sunesis Ph... | sunesis.com | $25M | United Sta... |
Mentions in press and media 4
| Date | Title | Description |
| 13.02.2015 | How illuminating: Invuity raises $20M for its surgical tools that light up | Invuity’s small devices actually are quite complex. Much of the eight years was spent on designers perfecting their design of the company’s illuminating clips, which snap onto the retractors that snake through tissue. “It’s like trying to s... |
| 01.05.2013 | Celator offers disruptive approach to chemo treatment options for acute myeloid leukemia | The Princeton, New Jersey-based treatment developer’s phase 3 clinical study will be a 300 patient, randomized, controlled study comparing CPX-351 to conventional cytarabine and daunorubicin therapy with a primary endpoint of overall surviv... |
| - | Celator offers disruptive approach to chemo treatment options for acute myeloid leukemia | A drug developer has done a final closing for its latest financing round to advance its new twist on chemotherapy treatment for 60- to 75-year-old patients with secondary acute myeloid leukemia through phase 3 clinical trials. Celator Pharm... |
| - | How illuminating: Invuity raises $20M for its surgical tools that light up | Invuity, a Bay Area medtech that builds surgical tools to help illuminate a patient’s innards during an operation, just raised $20 million in equity. The new dollars will help Invuity up commercialization efforts across its broad range of, ... |